Screener
CorMedix CRMD Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by CorMedix in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: CorMedix’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001410098-26-000021
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| STOCKHOLDERS’ EQUITY | ||
| Preferred stock - $0.001 par value: 2,000,000 shares authorized; 91,623 and 91,623 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | - | - |
| Common stock - $0.001 par value: 160,000,000 shares authorized; 78,395,299 and 79,260,667 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 78 | 79 |
| Accumulated other comprehensive income | 2 | 3 |
| Additional paid-in capital | 574,943 | 581,800 |
| Accumulated deficit | (137,974) | (176,575) |
| TOTAL STOCKHOLDERS’ EQUITY | $437,049 | $405,307 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $815,637 | $826,142 |
Item 1. Unaudited Condensed Consolidated Financial Statements.
FAQ
- What is CorMedix's total equity?
- CorMedix (CRMD) reported total equity of $437.05M in Q1 2026.
- How has CorMedix's total equity changed year-over-year?
- CorMedix's total equity increased by 280.4% year-over-year, from $114.89M to $437.05M.
- What is the long-term trend for CorMedix's total equity?
- Over 5 years (2020 to 2025), CorMedix's total equity has grown at a 55.7% compound annual growth rate (CAGR), from $44.22M to $405.31M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about CorMedix's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude